DAPA-CKD Data Put AstraZeneca’s Farxiga Out Front
A 39% relative risk reduction in the primary endpoint for the DAPA-CKD study and a 31% reduction in all-cause mortality prime Farxiga for a new chronic kidney disease indication following filings due in the next few months.
You may also be interested in...
Putting aside the coronavirus pandemic for a while, and turning to industry’s more bread and butter R&D activities, Scrip takes a look at the industry’s biggest clinical trial hits and misses of the year.
Keeping Track Of Breakthroughs: AZ Farxiga, ImmunoGen ADC For Hematologic Cancer, Inventiva NASH Candidate Earn Designation
The latest breakthrough therapy designation news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of developments in the global biopharmaceutical industry.